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We provide the reader with relevant data related to our recently
published paper, comparing two mathematical models to describe
prolactin turnover in rats following one or two doses of the
dopamine D2 receptor antagonists risperidone, paliperidone and
remoxipride, “A comparison of two semi-mechanistic models for
prolactin release and prediction of receptor occupancy following
administration of dopamine D2 receptor antagonists in rats”
(Taneja et al., 2016) [1]. All information is tabulated. Summary
level data on the in vitro potencies and the physicochemical
properties is presented in Table 1. Model parameters required to
explore the precursor pool model are presented in Table 2. In
Table 3, estimated parameter comparisons for both models arevier Inc. This is an open access article under the CC BY license
/j.ejphar.2016.07.005
etrics, Kinesis Pharma BV, Breda, The Netherlands.
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A. Taneja et al. / Data in Brief 8 (2016) 1433–14371434presented, when separate potencies are estimated for risperidone
and paliperidone, as compared to a common potency for both
drugs. In Table 4, parameter estimates are compared when the
drug effect is parameterized in terms of drug concentration or
receptor occupancy.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Pharmacology
ore speciﬁc sub-
ject area
Neuropsychopharmacologyype of data Tables
ow data was
acquired
Experimental study in male wistar rats, as described belowata format Processed tabulated data
xperimental
factors
P
a
lasma samples were collected for bioanalysis of risperidone, paliperidone,
nd remoxipride using an on-line solid phase extraction with liquid chro-
matography – tandem mass spectrometry method. Serum prolactin levels
were measured using an enzyme linked immunosorbent assay technique.xperimental
features
A
w
ll animal procedures were performed at Leiden University, in accordance
ith Dutch laws governing animal experimentation. Male Wistar rats,
received single intravenous doses of risperidone (2 mg/kg, n¼16) or paliper-
idone (0.5 mg/kg, n¼21). Plasma drug concentrations as well as plasma
prolactin levels were measured at pre-dose and at serial intervals post-dose.
In another study, remoxipride was administered to rats either as a single
intravenous dose of 4, 8 or 16 mg/kg (n¼10) remoxipride or two doses of
3.8 mg/kg at varying dosing intervals. Blood samples were serially collected.
Plasma concentrations of the drugs as well as prolactin were assayed using
validated analytical methods.ata source
location
D
L
epartment of Pharmacology, Leiden Academic center for Drug Research,
eiden.ata accessibility The data is within this article.D
Value of the data
Data can be used
 To compare experimental ﬁndings in literature with our model-based approach.
 As prior information, especially when the available data is scarce.
 For exploratory modeling.
 For translation from rat to humans.1. Data
The information is presented in 4 tables. Table 1 presents the in vitro inhibition constant (KI)
values in rat and humans and physicochemical characteristics of the antipsychotics risperidone,
paliperidone and remoxipride. Table 2 presents the pharmacokinetic–pharmacodynamic model
Table 2
Model parameters used for the simulations in exploratory model analysis. Pharmaco-
kinetic and pharmacodynamic parameters obtained from Kozielska et al. [3] and
Stevens et al. [4], respectively.
Parameter Estimate
CL (l h-1) 1.62
V1 (l) 1.29
Q (l h-1) 0.0882
V2 (l) 0.169
F 1
Ka (h-1) 2.84
Cprl,0 (ng ml-1) 6.2
Rform (ng ml-1 h-1) 35.3n
Kbase (h-1) 0.57
Kout (h-1) 5.7
Emax 25
EC50 (ng ml-1) 0.08
γ 1
Emax_pf 3.5
EC50_pf (ng ml-1) 12.4
CL ¼ clearance from the central compartment, V1 ¼ volume of the central compart-
ment, Q ¼ intercompartmental clearance, V2 ¼ volume of the peripheral compart-
ment, F ¼ bioavailability, Ka ¼ absorption constant, Cprl,0 ¼ plasma concentration of
prolactin in the absence of antipsychotic drug, Rform ¼ zero-order rate constant for
prolactin synthesis, Kbase ¼ ﬁrst-order rate constant of prolactin release from the pool,
Kout ¼ ﬁrst-order rate constant of elimination of prolactin from plasma, Emax ¼ max-
imum increase in the prolactin release from the pool, EC50 ¼ drug concentration at
half-maximal effect, γ ¼ slope parameter, Emax_pf ¼ maximum prolactin feedback,
EC50_pf ¼ plasma prolactin concentration at half-maximal effect.
n Rform is calculated as the product of Cprl,0 . Kout (equation (5) of Taneja et al. [1]).
Table 1
Overview of literature KI values and physicochemical characteristics of risperidone, paliperidone and remoxipride.
Risperidone Paliperidone Remoxipride
KI values (nM)
Ratn 2.55 2.74 370.66
Humann 2.18 2.08 165.75
Humannn 4.9 / 6 NA 243 / 125
Physicochemical characteristics
Protein binding % (rat)n 88.2 74.7 20-30
Protein binding % (human)n 90 77.4 80
Molecular weight (g/mol) 410.48 426.48 371.26
n Data on ﬁle.
nn Data from Richtand et al. [2]. Values depicted for D2 and D2 long receptor in vitro experimental KI.
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Table 3
Parameter comparison (relative standard error in %) of the pool model with different ECu50 for risperidone and paliperidone vs.
single ECu50 and the interaction model with different KI for risperidone and paliperidone vs single KI.
Estimates
Different ECu50 Single ECu50
Pool Model
52.1 (12) 48.7 (12)Rform (ng.ml-1h-1)
Kbase (h-1) 0.251 (12) 0.250 (12)
Kout (h-1) 6.96 (14) 6.57 (12)
Emax 3.5 FIXED 3.5 FIXED
ECu50 paliperidone (nM) 38.2 (52) 35.1 (51)
ECu50 risperidone (nM) 39.6 (142)
ECu50 remoxipride (nM) 95.2 (41) 94.8 (31)
γ 1 FIXED 1 FIXED
IIV Rform (%) 40 (18) 40 (18)
Residual error (%) 50 (7) 50 (7)
Minimization þþ þþ
Covariance þþ þþ
Objective Function Value 3454.764 3455.775
Interaction Model
23.8 (6) 23.8 (6)Kin,0 (ng.ml-1h-1)
Kout (h-1) 3.35 (10) 3.34 (9)
KDA (h-1) 5.12 (19) 5.51 (21)
DAs0 (dimensionless) 1000 FIXED 1000 FIXED
KI paliperidone (nM) 34.1 (11) 35.7 (12)
KI risperidone (nM) 47.7 (20)
KI remoxipride (nM) 370 (11) 360 (11)
γ 1 FIXED 1 FIXED
IIV Kin,0 (%) 40 (22) 40 (22)
Residual error (%) 56 (12) 56 (12)
Minimization þþ þþ
Covariance þþ þþ
Objective Function Value 3727.802 3726.086
Rform ¼ zero-order rate constant for prolactin synthesis, Kbase ¼ ﬁrst-order rate constant of prolactin release from the pool,
Kout ¼ ﬁrst-order rate constant of elimination of prolactin from plasma, Emax ¼ maximum increase in the prolactin release from
the pool, ECu50 ¼ unbound drug concentration at half-maximal effect, γ ¼ slope parameter, IIV ¼ inter-individual variability,
Kin,0 ¼ basal prolactin release rate, KDA ¼ ﬁrst-order turnover constant for hypothetical dopamine, DAs0 ¼ hypothetical scaled
dopamine concentration at baseline, KI ¼ drug potency parameter.
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to in Section 3.2, Fig. 5 of Taneja et al. [1]. Table 3 presents the model parameters assuming equal or
different potency of risperidone and paliperidone. Table 4 presents the model parameters obtained
with different parameterizations, assuming either unbound drug concentration or dopamine D2
receptor occupancy as the driving force for drug effect.2. Experimental design, materials and methods
Details of the experimental procedures have been described previously [1,5,6].
Table 4
Pool model: Comparison of parameter estimates with parameterization of drug effects as ECu50 as compared to RO50 (relative
standard error in %).
Parameter Estimates using
ECu50
Estimates using
RO50
Rform (ng.ml-1h-1) 45.7 (10) 49.8 (10)
Kbase (h-1) 0.25 (10) 0.226 (11)
Kout (h-1) 6.06 (12) 6.96 (13)
Emax 3.5 FIXED 3.5 FIXED
ECu50 risperidone/paliperidone
(nM)
35.1 (51) n
ECu50 remoxipride (nM) 94.8 (31) n
RO50 (%) NA 28.7 (27)
γ 1 FIXED 1 FIXED
IIV Kout (%) 42.1 (18) 42.3 (18)
Residual error - proportional (%) 47.2 (4) 37.4 (8)
Residual error - additive (ng ml-1) NE 2.68 (29)
Minimization þþ þþ
Covariance step þþ þþ
Objective Function Value 3434.44 3430.56
Rform ¼ zero-order rate constant for prolactin synthesis, Kbase ¼ ﬁrst-order rate constant of prolactin release from the pool,
Kout ¼ ﬁrst-order rate constant of elimination of prolactin from plasma, Emax ¼ maximum increase in the prolactin release from
the pool, ECu50 ¼ unbound drug concentration at half-maximal effect, RO50 ¼ receptor occupancy at half-maximal effect,
γ ¼ slope parameter, IIV ¼ inter-individual variability.
NA ¼ not applicable.
NE ¼ not estimated.
n KI risperidone/paliperidone ¼ 2.55 nM, KI remoxipride ¼ 370.66 nM (ﬁxed to in vitro experimental values).
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